CNS Pharmaceuticals (NASDAQ: CNSP)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-12 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.110 | -0.070 | 0.0400 | ||||
REV | 0 |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of CNS Pharmaceuticals (NASDAQ: CNSP) through any online brokerage.
Other companies in CNS Pharmaceuticals’s space includes: Cingulate (NASDAQ:CING), Dermata Therapeutics (NASDAQ:DRMA), Baudax Bio (NASDAQ:BXRX), Kiora Pharmaceuticals (NASDAQ:KPRX) and Universe Pharmaceuticals (NASDAQ:UPC).
The latest price target for CNS Pharmaceuticals (NASDAQ: CNSP) was reported by Brookline Capital on Tuesday, February 2, 2021. The analyst firm set a price target for 10.00 expecting CNSP to rise to within 12 months (a possible 3673.58% upside). 0 analyst firms have reported ratings in the last year.
The stock price for CNS Pharmaceuticals (NASDAQ: CNSP) is $0.265 last updated July 1, 2022, 8:00 PM UTC.
There are no upcoming dividends for CNS Pharmaceuticals.
CNS Pharmaceuticals’s Q2 earnings are confirmed for Friday, August 12, 2022.
There is no upcoming split for CNS Pharmaceuticals.
CNS Pharmaceuticals is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.